tbuckley/cabot-search huggingface dataset:
Evaluating integrated surveillance of antimicrobial resistance: experiences from use of three evaluation tools
Authors: Liza Rosenbaum Nielsen, Lis Alban, Johanne Ellis-Iversen, Koen Mintiens, Marianne Sandberg
Journal: Clinical Microbiology and Infection (2020)

Integrated antimicrobial resistance (AMR) surveillance programmes require regular evaluation to ensure they are fit for purpose and that all actors understand their responsibilities. This will strengthen their relevance for the clinical setting, which depends heavily on continued access to effective treatment options. Several evaluation tools addressing different surveillance aspects are available.The aim was to understand the strengths and weaknesses of three evaluation tools, and to improve guidance on how to choose a fit-for-purpose tool.Three tools were assessed: (a) AMR-PMP-the Progressive Management Pathway tool on AMR developed by the Food and Agriculture Organization (FAO) of the United Nations, (b) NEOH developed by the EU COST Action 'Network for Evaluation of One Health' and (c) SURVTOOLS developed in an FP7-EU project 'RISKSUR'. Each tool was assessed with regard to contents, required evaluation processes including stakeholder engagement and resource demands, integration coverage across relevant sectors and applicability. They were compared using a predefined scoring scheme and a strengths-weaknesses-opportunities-threats (SWOT)-like format for commenting.All three tools address multiple decision-making levels and aspects of stakeholder engagement. NEOH focuses on system features, learning, sharing, leadership and infrastructure, and requires a description of the underlying system in which AMR develops. AMR-PMP focuses on four areas: awareness, evidence, governance and practices and assesses the implementation degree of pre-chosen aspects within these areas. This requires less of the evaluator, but warrants participation of multiple stakeholders. SURVTOOL provides information and references on how to evaluate effectiveness, process and comprehensiveness of surveillance programmes. All three tools require veterinary epidemiology expertise and varying levels of evaluation methodology training to use appropriately.The tools covered AMR surveillance and One Health aspects to varying degrees. This study provides guidance on aspects to consider when choosing between available tools and embarking on an evaluation of integrated surveillance.
TCTAP A-111 Twelve-month Clinical Outcomes According to Age in Patients Following Successful Unprotected Left Main Percutaneous Coronary Intervention
Authors: Se Yeon Choi, Seung-Woon Rha, Byoung Geol Choi, Jae Kyeong Byun, Min Shim, Jun Hyuk Kang, Woo Hyeun Kim, Sung Hun Park, Eun Jin Park, Jah Yeon Choi, Sunki Lee, Li Hu, Jin Oh Na, Cheolung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer
Authors: Gregory L. Branigan, Maira Soto, Leigh Neumayer, Kathleen Rodgers, Roberta Diaz Brinton
Journal: JAMA Network Open (2020)

<h3>Importance</h3> The association between exposure to hormone-modulating therapy (HMT) as breast cancer treatment and neurodegenerative disease (NDD) is unclear. <h3>Objective</h3> To determine whether HMT exposure is associated with the risk of NDD in women with breast cancer. <h3>Design, Setting, and Participants</h3> This retrospective cohort study used the Humana claims data set from January 1, 2007, to March 31, 2017. The Humana data set contains claims from private-payer and Medicare insurance data sets from across the United States with a population primarily residing in the Southeast. Patient claims records were surveyed for a diagnosis of NDD starting 1 year after breast cancer diagnosis for the duration of enrollment in the claims database. Participants were 57 843 women aged 45 years or older with a diagnosis of breast cancer. Patients were required to be actively enrolled in Humana claims records for 6 months prior to and at least 3 years after the diagnosis of breast cancer. The analyses were conducted between January 1 and 15, 2020. <h3>Exposure</h3> Hormone-modulating therapy (selective estrogen receptor modulators, estrogen receptor antagonists, and aromatase inhibitors). <h3>Main Outcomes and Measures</h3> Patients receiving HMT for breast cancer treatment were identified. Survival analysis was used to determine the association between HMT exposure and diagnosis of NDD. A propensity score approach was used to minimize measured and unmeasured selection bias. <h3>Results</h3> Of the 326 485 women with breast cancer in the Humana data set between 2007 and 2017, 57 843 met the study criteria. Of these, 18 126 (31.3%; mean [SD] age, 76.2 [7.0] years) received HMT, whereas 39 717 (68.7%; mean [SD] age, 76.8 [7.0] years) did not receive HMT. Mean (SD) follow-up was 5.5 (1.8) years. In the propensity score–matched population, exposure to HMT was associated with a decrease in the number of women who received a diagnosis of NDD (2229 of 17 878 [12.5%] vs 2559 of 17 878 [14.3%]; relative risk, 0.89; 95% CI, 0.84-0.93;<i>P</i> &lt; .001), Alzheimer disease (877 of 17 878 [4.9%] vs 1068 of 17 878 [6.0%]; relative risk, 0.82; 95% CI, 0.75-0.90;<i>P</i> &lt; .001), and dementia (1862 of 17 878 [10.4%] vs 2116 of 17 878 [11.8%]; relative risk, 0.88; 95% CI, 0.83-0.93;<i>P</i> &lt; .001). The number needed to treat was 62.51 for all NDDs, 93.61 for Alzheimer disease, and 69.56 for dementia. <h3>Conclusions and Relevance</h3> Among patients with breast cancer, tamoxifen and steroidal aromatase inhibitors were associated with a decrease in the number who received a diagnosis of NDD, specifically Alzheimer disease and dementia.
TCT-767 Treatment of Bio-Prosthetic Valve Deterioration Using The Valve-in-Valve Technique
Authors: Pablo Codner, Abid Assali, Hana Vaknin-Assa, Yaron Shapira, Gabriel Greenberg, Katia Orvin, Marina Kupershmidt, Tamir Bental, Alexander Sagie, Ran Kornowski
Journal: Journal of the American College of Cardiology (2014)
Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy
Authors: E.P. Hui, W.F. Li, B.B. Ma, W.K.J. Lam, K.C.A. Chan, F. Mo, Q.Y.H. Ai, A.D. King, C.H. Wong, R. Guo, D.M.C. Poon, M. Tong, L. Li, T.K.H. Lau, K.C.W. Wong, D.C.M. Lam, Y.M.D. Lo, J. Ma, A.T.C. Chan
Journal: Annals of Oncology (2020)
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
Authors: Jing Yu, Wen Ouyang, Melvin L. K. Chua, Conghua Xie
Journal: JAMA Oncology (2020)

This cross-sectional study reviews the medical records of 1524 patients with cancer treated at a single tertiary care hospital in Wuhan, China, to evaluate the characteristics associated with transmission of the SARS-CoV-2 virus.
IMPACT OF LENGTH AND HYDROPHILIC COATING OF THE INTRODUCER SHEATH ON RADIAL ARTERY SPASM DURING TRANSRADIAL CORONARY INTERVENTION: A RANDOMISED STUDY
Authors: Sudhir Rathore, Rodney H. Stables, Maheswar Pauriah, Abdul Hakeem, Joseph D. Mills, Nick Palmer, Raphael A. Perry, John L. Morris
Journal: Journal of the American College of Cardiology (2010)
Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
Authors: Michael Koller, Omar Shamieh, Marianne J Hjermstad, Kjersti Hornslien, Teresa Young, Tara Chalk, Georgios Ioannidis, Amelie Harle, Colin D Johnson, Krzysztof A Tomaszewski, Samantha Serpentini, Monica Pinto, Lotte van der Weijst, Annelies Janssens, Ofir Morag, Wei-Chu Chie, Juan I Arraras, Cecilia Pompili, Wolfgang Jungraithmayr, Marlene Hechtner, Despina Katsochi, Karolina Müller, Laura Gräfenstein, Christian Schulz, Andrew Bottomley
Journal: The Lancet Oncology (2020)
右左冠動脈,左内胸動脈,気管支動脈から冠動脈へfistulaを認めたシェーグレン症候群の一例
Authors: 升谷悦子, 山形寿生, 福田昭宏, 北山道彦, 梶波康二, 大久保信二, 金光政右, 津川博一, 竹越のぼる
Journal: Circulation (2002)
TCT-351 Coronary sinus reducer implantation for the treatment of chronic refractory angina: a single center experience
Authors: Francesco Giannini, Andrea Aurelio, Richard Jabbour, Luca Angelo Ferri, Massimo Slavich, Roberto Spoladore, Marco Spartera, Alessia Faccini, Marco Ancona, Antonio Mangieri, Damiano Regazzoli, Alaide Chieffo, Matteo Montorfano, Azeem Latib, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
TCTAP A-113 The Association of Serum Ferritin and 1-year Mortality in Patients with Critical Limb Ischemia
Authors: Sang-Ho Park, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Yoonjee Park, Akkala Raghavender Goud, Hu Li, Sunki Lee, Ji Bak Kim, Sung Il Im, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2014)
Leaking chemokines confuse neutrophils
Authors: Alex Marki, Klaus Ley
Journal: Journal of Clinical Investigation (2020)

The physical integrity of endothelial cells (ECs) lining the blood vessels regulates the inflammatory response. Both innate immunity and inflammatory disorders hinge on the EC-neutrophil interaction. Neutrophil binding, rolling, and migrating along and between ECs is associated with vascular permeability. In this issue of the JCI, Owen-Woods et al. tracked neutrophils in vivo in venules of mouse striated muscle and revealed how endothelial permeability can affect neutrophil trafficking. Strikingly, many neutrophils that migrated between EC junctions were able to rejoin the blood circulation. Further, the chemokine and neutrophil chemoattractant, CXCL1, drove this reverse transendothelial migration (rTEM). This paradigm-shifting study provides a mechanism for distal organ damage as well as an explanation for sepsis-associated acute respiratory distress syndrome.
The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis
Authors: Christopher A. Mecoli, Ami A. Shah, Francesco Boin, Fredrick M. Wigley, Laura K. Hummers
Journal: Arthritis & Rheumatology (2020)

Objective In cross‐sectional studies, pulmonary hypertension (PH) and ischemic digital lesions are 2 scleroderma vascular outcomes associated with abnormalities in biomarkers of angiogenesis. The clinical usefulness of these biomarkers is unknown, in part due to lack of data on longitudinal measurement. This prospective longitudinal study was undertaken to evaluate vascular biomarker measurements in patients with systemic sclerosis (SSc) over time. Methods We conducted a prospective cohort study of 300 patients with SSc who were followed up for at least a 5‐year period and lacked evidence of PH and/or active ischemic digital lesions at enrollment. Levels of hepatocyte growth factor (HGF), soluble Flt‐1 (sFlt‐1), soluble endoglin, endostatin, and placental growth factor (PLGF) were obtained at multiple time points and assessed for their ability to predict the development of PH/ischemic digital lesions. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated. Results Forty‐six patients (15%) developed PH and 69 patients (23%) developed an ischemic digital lesion. In time‐to‐event analyses, the following 3 biomarkers measured at cohort entry were found to be significantly associated with the development of PH: HGF (HR 1.99 [95% CI 1.24–3.17], P = 0.004), sFlt‐1 (HR 3.04 [95% CI 1.29–7.14], P = 0.011), and PLGF (HR 2.74 [95% CI 1.32–5.69], P = 0.007). As time approaching PH diagnosis decreased, there was no corresponding increase in any biomarker level. Upon converting each continuous vascular biomarker into a binary variable, a dose‐response relationship was observed for the number of elevated biomarkers at cohort entry and the risk of developing PH. With each additional elevated biomarker at cohort entry, there was a 78% increase in the risk of developing PH (HR 1.78 [95% CI 1.2–2.6], P = 0.004). Conclusion These data suggest that molecules involved in angiogenesis reflect vascular perturbation, and that elevations in these biomarkers at first encounter can indicate patients who are at risk of PH development.
TCTAP A-133 Impact of Percutaneous Coronary Intervention on 12-month Chronic Total Occlusion Outcomes in Patients with Myocardial Infarction
Authors: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Yoonjee Park, Akkala Raghavender Goud, Hu Li, Sunki Lee, Ji Bak Kim, Sung Il Im, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2014)
CATHETERIZATION FOR CONGENITAL HEART DISEASE ADJUSTMENT FOR RISK METHOD (CHARM)
Authors: Lisa T. Bergersen, Kimberlee Gauvreau, Audrey Marshall, Jacqueline Kreutzer, Robert Beekman, Russel Hirsch, Susan Foerster, David Balzer, Julie Vincent, William Hellenbrand, Ralf Holzer, John Cheatham, John Moore, Grant Burch, Laurie Armsby, James Lock, Kathy Jenkins
Journal: Journal of the American College of Cardiology (2011)
IMPACT OF INTRAVASCULAR IMAGING METHODS FOR OPTIMAL SCAFFOLD IMPLANTATION REDUCING THROMBOSIS AFTER ABSORB BVS IN A REAL WORLD SETTING: IDENTIFICATION OF FACTORS RELATED TO STENT FAILURE
Authors: Sergio Tarbine, Costantino Costantini, Costantino Costantini, Rafael Macedo, Marcelo de Freitas Santos, Daniel Zanuttini, Marco A. Denk
Journal: Journal of the American College of Cardiology (2018)
SHORT-TERM VERSUS LONG-TERM DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENT IMPLANTATION IN ELDERLY PATIENTS: A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM SIX RANDOMIZED TRIALS
Authors: Seung-Yul Lee, Myeong-Ki Hong, Tullio Palmerini, Hyo-Soo Kim, Marco Valgimigli, Fausto Feres, Antonio Colombo, Martine Gilard, Dong-Ho Shin, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Gregg Stone
Journal: Journal of the American College of Cardiology (2018)
INTER-CORE LAB VARIABILITY IN ANALYZING QUANTITATIVE CORONARY ANGIOGRAPHY FOR BIFURCATION LESIONS: A POST-HOC ANALYSIS OF A RANDOMIZED TRIAL
Authors: Maik J. Grundeken, Yuki Ishibashi, Philippe Genereux, Laura Lasalle, Joanna Wykrzykowska, Marie-angèle Morel, Jan Tijssen, Robbert de Winter, Chrysafios Girasis, Hector Garcia Garcia, Yoshi Onuma, Martin Leon, Patrick W.J.C. Serruys
Journal: Journal of the American College of Cardiology (2015)
Gastroesophageal reflux disease after peroral endoscopic myotomy is unpredictable, but responsive to proton pump inhibitor therapy: a large, single-center study
Authors: Zaheer Nabi, Mohan Ramchandani, Rama Kotla, Manu Tandan, Rajesh Goud, Santosh Darisetty, G. Venkat Rao, D. Nageshwar Reddy
Journal: Endoscopy (2020)

Abstract Background Gastroesophageal reflux disease (GERD) is an important concern after peroral endoscopic myotomy (POEM). However, there are limited data on the risk factors for post-POEM GERD and its responsiveness to proton pump inhibitors (PPIs). In this study, we aimed to analyze the variables affecting the occurrence of GERD and its response to PPI therapy. Methods Consecutive patients with idiopathic achalasia who underwent POEM (December 2016 to January 2018) were evaluated for GERD using 24-hour pH impedance, esophagogastroduodenoscopy (EGD), and symptoms. Multivariate analysis was performed to identify the variables affecting the incidence of post-POEM GERD. Results A total of 209 patients with esophageal motility disorders, including 194 patients with non-sigmoid achalasia, underwent POEM during the study period. Comprehensive evaluation of GERD was completed on 167 patients (86.1 %): 47.3 % women with a mean (standard deviation) age of 41 (14.42) years and body mass index of 22.2 (3.89) kg/m2; the majority (70.7 %) were treatment naïve. A high DeMeester score (&gt; 14.72), reflux esophagitis, and symptomatic GERD were identified in 47.9 %, 41.9 %, and 29.3 % of patients, respectively. On logistic regression analysis, type of achalasia, technique of POEM (anterior vs. posterior), pre- or post-POEM esophageal manometry variables, and patient characteristics were not associated with post-POEM GERD. Erosive esophagitis responded to PPI therapy in the majority of patients (81.4 %). Conclusion The incidence of GERD is high after POEM. Most of the reflux esophagitis is mild and responsive to PPI therapy. There are no procedural or patient-related variables that appear to affect the incidence of post-POEM GERD.
Bcl-6-directed follicular helper T cells promote vascular inflammatory injury in diabetic retinopathy
Authors: Yan Liu, Ziqi Yang, Peilong Lai, Zijing Huang, Xiaowei Sun, Tian Zhou, Chang He, Xialin Liu
Journal: Theranostics (2020)

Diabetic retinopathy (DR) is a vision-threatening complication of diabetes mellitus characterized by chronic retinal microvascular inflammation. The involvement of CD4+ T cells in retinal vascular inflammation has been considered, but the specific subset and mechanism of T cell-mediated response during the process remains unclear. Here, we aim to investigate the potential role of follicular helper T (Tfh) cells, a newly identified subset of CD4+ T cells in retinal vascular inflammation in DR. Methods: Patients with DR were enrolled and the PD-1+CXCR5+CD4+ Tfh cells were detected in the peripheral blood by flow cytometry. The streptozotocin (STZ)-induced DR model and oxygen-induced retinopathy (OIR) model were established, and 79-6, an inhibitor of Bcl-6, was injected intraperitoneally to suppress Tfh cells. The Tfh cells-related genes were investigated in the spleen, lymph nodes, and retina of mice by flow cytometry, immunofluorescence, and qPCR. Results: The Tfh cells expanded in the circulation of patients with DR and also increased in circulation, lymph nodes and retinal tissues from the STZ-induced DR mice and OIR mice. Notably, inhibition of Bcl-6, a critical transcription factor for Tfh cells development, prevented upregulation of Tfh cells and its typical IL-21 cytokine, and ameliorated vascular leakage in DR mice or retinal angiogenesis in OIR mice, indicating that Bcl-6-directed Tfh cells could promote vascular inflammation and angiogenesis. Conclusions: Our results suggested that excessive Bcl-6-directed Tfh cells represent an unrecognized feature of DR and be responsible for the retinal vascular inflammation and angiogenesis, providing opportunities for new therapeutic approaches to DR.
Effects of Interleukin-1β Inhibition on Incident Anemia
Authors: Mounica Vallurupalli, Jean G. MacFadyen, Robert J. Glynn, Tom Thuren, Peter Libby, Nancy Berliner, Paul M Ridker
Journal: Annals of Internal Medicine (2020)

Background: Inflammatory cytokines, such as interleukin (IL)-1β, alter iron homeostasis and erythropoiesis, resulting in anemia, but whether inhibition of IL-1β can reverse these effects is unclear. Objective: To determine whether IL-1β inhibition with canakinumab reduces incident anemia and improves hemoglobin levels among those with prevalent anemia. Design: Exploratory analysis of a randomized controlled trial. (ClinicalTrials.gov: NCT01327846) Setting: Many clinical sites in 39 countries. Participants: 8683 CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) participants without anemia at trial entry and 1303 with prevalent anemia at trial entry. Intervention: Random assignment to receive placebo or canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months. Measurements: Primary outcome was incident anemia (hemoglobin level <130 g/L in men or <120 g/L in women). Results: Anemia incidence increased with rising baseline levels of high-sensitivity C-reactive protein (hsCRP), and both hsCRP and IL-6 decreased among participants receiving canakinumab compared with the placebo group. During a median follow-up of 3.7 years, participants without baseline anemia who received canakinumab at any dosage had significantly less incident anemia than those who received placebo (hazard ratio, 0.84 [95% CI, 0.77 to 0.93]; P < 0.001). Compared with placebo, the greatest benefits of IL-1β inhibition on incident anemia were observed among participants with the most robust anti-inflammatory response, an effect corroborated in formal mediation analyses. Among those with baseline anemia, canakinumab increased mean hemoglobin levels by 11.3 g/L (P < 0.001) compared with placebo after 2 years of treatment. Canakinumab increased the risk for infection and was associated with mild cases of thrombocytopenia and neutropenia, none of which was grade 3 or higher. Limitation: CANTOS was not designed to assess the cause of anemia in individual trial participants. Conclusion: These exploratory analyses of randomized trial data provide proof of principle that inflammation inhibition, at least through the IL-1β/IL-6 signaling pathway, reduces the incidence of anemia and improves hemoglobin levels in patients with anemia. Primary Funding Source: Novartis Pharmaceuticals.
Ultrasound Responsive Noble Gas Microbubbles for Applications in Image‐Guided Gas Delivery
Authors: Rajarshi Chattaraj, Misun Hwang, Serge D. Zemerov, Ivan J. Dmochowski, Daniel A. Hammer, Daeyeon Lee, Chandra M. Sehgal
Journal: Advanced Healthcare Materials (2020)

Abstract Noble gases, especially xenon (Xe), have been shown to have antiapoptotic effects in treating hypoxia ischemia related injuries. Currently, in vivo gas delivery is systemic and performed through inhalation, leading to reduced efficacy at the injury site. This report provides a first demonstration of the encapsulation of pure Xe, Ar, or He in phospholipid‐coated sub‐10 µm microbubbles, without the necessity of stabilizing perfluorocarbon additives. Optimization of shell compositions and preparation techniques show that distearoylphosphatidylcholine (DSPC) with DSPE‐PEG5000 can produce stable microbubbles upon shaking, while dibehenoylphosphatidylcholine (DBPC) blended with either DSPE‐PEG2000 or DSPE‐PEG5000 produces a high yield of microbubbles via a sonication/centrifugation method. Xe and Ar concentrations released into the microbubble suspension headspace are measured using GC‐MS, while Xe released directly in solution is detected by the fluorescence quenching of a Xe‐sensitive cryptophane molecule. Bubble production is found to be amenable to scale‐up while maintaining their size distribution and stability. Excellent ultrasound contrast is observed in a phantom for several minutes under physiological conditions, while an intravenous administration of a bolus of pure Xe microbubbles provides significant contrast in a mouse in pre‐ and post‐lung settings (heart and kidney, respectively), paving the way for image‐guided, localized gas delivery for theranostic applications.
TCT-195 Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization: Two-year Outcomes from the Randomized BIOFLOW V Trial
Authors: David Kandzari, Jacques J. Koolen, Gheorghe Doros, Joseph Massaro, Hector Garcia-Garcia, Johan Bennett, Ariel Roguin, Elie Gharib, Donald Cutlip, Ron Waksman
Journal: Journal of the American College of Cardiology (2018)
TCT-234 3-Year Clinical Outcome of the PRISON-IV Trial: Ultra-Thin Struts Versus Conventional Drug Eluting Stents in Total Coronary Occlusions
Authors: Carlo Zivelonghi, Pierfrancesco Agostoni, Koen Teeuwen, Rene van der Schaaf, Jose P.S. Henriques, Paul Vermeersch, Jan Tijssen, Maarten Suttorp
Journal: Journal of the American College of Cardiology (2019)